A Study Of PF-06664178 In Patients With Advanced Solid Tumors

Summary

To assess the safety and tolerability at increasing dose levels of PF-06664178 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Timeline

Start

2014-08

Primary completion

2016-06

Completion

2016-06

Outcome

Outcome not reported

Stopped (Business): “The study was prematurely discontinued due to a business-related decision on 09-FEB-2016. The decision to terminate the trial was based on the overall results.”

Drugs

Indications